Late Discovery & Investigative Research

NGT BioPharma Consultants understand the challenges companies face when selecting a candidate molecule(s) to advance into preclinical development. To increase the efficiency and effectiveness of this process, we work collaboratively with our clients to provide a clear assessment of a potential asset’s attributes, including risks, to ensure critical experiments are prioritized. 

We generate fit-for-purpose late discovery and investigative research plans for our clients by leveraging our team’s collective knowledge and experience in small and large molecules (Mabs, duobodies, proteins, cell therapy, gene therapy, and other new modalities).
Our advice, and recommendations, also leverages our broader team’s drug development expertise in the Nonclinical Sciences, CMC, Regulatory and Quality/Compliance disciplines.

Although NGT is neither a laboratory or manufacturing services provider, we can serve as your single point of contact to our network of reputable CROs and CDMOs.

Screen Shot 2022-06-23 at 6.23.37 PM

For more information please contact:

Michael K. O'Brien


Rachel Franckowiak

Senior Director, Administration